linjc16/ctgov huggingface dataset:
Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair

Study Overview
=================
Brief Summary
-----------------
Purpose: The effect of intravenous glutamate infusion on myocardial diastolic function and overall hemodynamics were studied in patients undergoing elective aortic valve replacement with severe aortic stenosis and associated left ventricular hypertrophy . Methods: 25 patients will be included in this double-blind randomized placebo-controlled study. Glutamate was administered intravenously immediately after aortic cross-clamp release. The patients receive either a low dose of 30mg kg-1 h-1 (LG-group) or high dose of 60 mg kg-1 h-1 (HG-group) or placebo (P-group) at a rate of 3.3ml kg-1h-1 for 2h. Transesophageal echocardiography (TEE) is used to measure diastolic and systolic ventricular function before sternotomy (T0), and 2h (T2), 3h (T3) and 6h (T4) after release of cross clamp. Additionally routine hemodynamic parameters are measured intraoperatively.

Official Title
-----------------
Glutamate Infusion in Hypertrophied Ventricle After Aortic Valve Replacement - a Randomized Trial

Conditions
-----------------
Hypertrophy, Left Ventricular, Aortic Stenosis, Myocardial Ischemia, Cardiopulmonary Bypass

Intervention / Treatment
-----------------
* Drug: LG-group
* Drug: HG-group
* Drug: Placebo-group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: severe aortic stenosis left ventricular hypertrophy of more than 10mm IVS thickness normal ejection fraction SR Exclusion Criteria: moderately or severely reduced systolic left ventricular function (ejection fraction <30%) atrial fibrillation or flutter intolerance to glutamate.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: LG-group|nan|
|Drug: HG-group|nan|
|Drug: Placebo-group|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| flow propagational velocity |  |  | 
| Isovolumic relaxation time |  |  | 
| E-velocity |  |  | 
| A-velocity |  |  | 
| E/A ratio |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ejection fraction |  |  | 
| cardiac output |  |  | 
| mitral ring motion |  |  |
Comparison of Stability and Outcomes in Single-radius Femoral Component for Total Knee Arthroplasty

Study Overview
=================
Brief Summary
-----------------
This is a comparison of the functional results and Varus-Valgus Stability in Single-radius versus Multi-radius Femoral Component for Total Knee Arthroplasty.

Detailed Description
-----------------
Recently, femoral designs based on a sagittal single radius were designed to allow better mid-flexion stability and extensor function after total knee arthroplasty. The purpose of this study was to compare mid-flexion stability and clinical outcomes in patients that received TKA using either a single-radius femoral design or multi-radius femoral design.

Official Title
-----------------
Study of Compare Mid-flexion Stability and Clinical Outcomes in Single-radius Femoral Design or Multi-radius Femoral Design.

Conditions
-----------------
Osteoarthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: followed for a minimum of two years. Exclusion Criteria: Not followed for a minimum of two years.

Ages Eligible for Study
-----------------
Minimum Age: 48 Years
Maximum Age: 84 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stability, single-radius, multi-radius, total knee arthroplasty
Impact of COVID-19 on Psoriasis Practice

Study Overview
=================
Brief Summary
-----------------
COVID-19 had a major impact on dermatology practice globally with special emphasis on chronic diseases e.g. psoriasis. The main objective of this work is to investigate the effect of COVID-19 pandemic on psoriasis management. This work is designed as a cross-sectional survey based on a questionnaire directed to Egyptian dermatologists.

Official Title
-----------------
Impact of COVID-19 on Psoriasis Practice: A Cross Sectional Study

Conditions
-----------------
Psoriasis, Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Egyptian Dermatologists

Ages Eligible for Study
-----------------
Minimum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaire to assess 1) Prescription pattern for Psoriasis patients during COVID-19 2) Management pattern for Psoriasis patients during COVID-19 |  | 2-4 weeks | 
| Questionnaire to assess 1) Impact of COVID-19 on the course of psoriasis in patients 2) Impact of COVID-19 on the psoriasis patients behaviour |  | 2-4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Psoriasis, coronavirus, Sars-Cov-2
Effect of Deep Brain Stimulation on Lower Urinary Tract Function

Study Overview
=================
Brief Summary
-----------------
The precise mechanisms underlying cerebral regulation of lower urinary tract (LUT) function are still poorly understood. Patients with deep brain stimulation (DBS) offer the unique opportunity to investigate the role of different cerebral centers on LUT function. We hypothesize that DBS has a significant effect on LUT function and that these effects depend on the specific stimulated cerebral center.

Official Title
-----------------
Effect of Deep Brain Stimulation (DBS) on Lower Urinary Tract (LUT) Function

Conditions
-----------------
Movement Disorder, Urinary Tract Disease

Intervention / Treatment
-----------------
* Procedure: deep brain stimulation ON
* Procedure: Deep brain stimulation OFF


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with deep brain stimulation (DBS) Exclusion Criteria: Pregnancy Age <18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br>Urodynamic investigation with deep brain stimulation ON | Procedure: deep brain stimulation ON<br>* deep brain stimulation in the ON state<br>|
| Experimental: B<br>Urodynamics with deep brain stimulation OFF | Procedure: Deep brain stimulation OFF<br>* Urodynamic investigation with deep brain stimulation in the OFF state<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of deep brain stimulation (DBS) on urodynamic parameters |  | immediately and 3 months after study inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in questionnaire data due to deep brain stimulation (DBS) |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
deep brain stimulation, urodynamics
Study of Rifaximin in Minimal Hepatic Encephalopathy

Study Overview
=================
Brief Summary
-----------------
Rifaximin therapy will improve brain functioning on MRI scanning and change the microbiome and metabolome.

Official Title
-----------------
Effect of Rifaximin Therapy on Brain Activation in Patients With Minimal Hepatic Encephalopathy Using Functional MR, MR Spectroscopy,Diffusion Tensor Imaging Microbiome and Metabolome: a Prospective Trial

Conditions
-----------------
Minimal Hepatic Encephalopathy

Intervention / Treatment
-----------------
* Drug: Rifaximin
* Drug: rifaximin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-65 years cirrhosis diagnosed by clinical or biopsy grounds Minimal hepatic encephalopathy defined by impaired performance on at least 2 of the following: number connection tests A/B, digit symbol and block design tests (NCT-A, NCT-B, DST and BDT) compared to age and education-matched controls. No contraindications to MRI TIPS (transjugular intra-hepatic porto-systemic shunt) procedure or elective surgery planned within the next 8 weeks Exclusion Criteria: Current therapy with lactulose, rifaximin or other treatment for hepatic encephalopathy. Prior episodes of overt HE MMSE <25 TIPS placement Unable to give informed consent. Contra-indications to MRI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Rifaximin<br> | Drug: Rifaximin<br>* 550mg BID open-label<br>* Other names: xifaxan;Drug: rifaximin<br>* 550mg PO BID<br>* Other names: xifaxan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| brain activation on fMRI |  | 2 months | 
| Microbiome constituents |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| brain edema and brain metabolite concentration |  | 2 months | 
| Metabolome of urine and serum |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
minimal hepatic encephalopathy, cirrhosis, complications
The Molecular Mechanism and the Role of NRAMP 1gene on Tuberculosis in Taiwan Aboriginal Tribes Population

Study Overview
=================
Brief Summary
-----------------
The human homologue of mice natural-resistance-associated macrophage protein 1 (Nramp 1) gene, NRAMP 1, has been reported to play a role in the susceptibility to tuberculosis in humans. The aboriginal population in Taiwan has a 5-fold higher prevalence of tuberculosis than the Han Chinese. Whether genetic factors such as NRAMP 1 polymorphisms play a role in the prevalence of tuberculosis in Taiwanese aboriginals should be clarified.

Official Title
-----------------
The Molecular Mechanism and the Role of NRAMP 1gene on Tuberculosis in Taiwan Aboriginal Tribes Population

Conditions
-----------------
Tuberculosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The NRAMP 1 polymorphism of tuberculous patients in Taiwan. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
VDR and TFIP11 Gene Polymorphism and Gene-environmental Interaction in Adults

Study Overview
=================
Brief Summary
-----------------
VDR and TFIP11 Gene polymorphism and gene-environment interactions on caries etiology and susceptibility in adults.

Detailed Description
-----------------
To date, genes can be grouped into categories based on the factor influencing dental caries. The major candidate gene categories to date include enamel formation genes, immune response genes, genes related to saliva, and genes related to taste and dietary habits. TFIP11 and VDR genes are related to enamel formation genes

Official Title
-----------------
Association Between Enamel Gene Variants and Dental Caries in Adults

Conditions
-----------------
Low Caries Experience, High Caries Experience

Intervention / Treatment
-----------------
* Genetic: high caries experience


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult be between 24 and 40 years old subject has DMFT (Decayed, Missing, Filled, Permanent Tooth) DMFT≤4 , or, DMFT>13.9 Exclusion Criteria: systemic or genetic disorders orthodontic appliances pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 24 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| high caries experience<br>80 adults will be allowed in the high caries experience group according to DMFT index DMFT>13.9 | Genetic: high caries experience<br>* DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit<br>* Other names: DNA isolation, genotyping;|
| low caries experience<br>80 adults will be allowed in the high caries experience group according toDMFT index DMFT≤4 | Genetic: high caries experience<br>* DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit<br>* Other names: DNA isolation, genotyping;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| past caries experience | Each tooth will be examined and recorded as decayed, missing, or filled | 3 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plaque index | The plaque amount is scored by using Silness&Löe Plaque Index plaque index PI<1.0 healthy PI 1.1-2.0 mild PI>2 high plaque | 3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
caries experience, VDR, TFIP11, enviromental risk factor
Ph II Early BC Pre-Surgical Biologic Study

Study Overview
=================
Brief Summary
-----------------
A pre-surgery study to assess changes that occur in human breast cancer material and normal skin after a short course of treatment with Iressa.

Official Title
-----------------
A PreSurgical Study to Evaluate Molecular Alterations That Occur in Human Breast Cancer Tissue and Normal Skin After Short Term Exposure to ZD1839 (IRESSA) and to Correlate These Alterations With Pharmacokinetic Parameters.

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Drug: Gefitinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Invasive breast cancer, Aged 18 years or older, Not more than 28 days from initial diagnosis Exclusion Criteria: Pregnant or lactating patients, Prior or current radiotherapy for breast cancer, Known allergy reaction to Iressa

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Gefitinib|Iressa|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Molecular alterations occuring in breast cancer tissue following Iressa treatment |  | At time of diagnosis and time of patient surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Molecular alterations occurring in normal skin tissue following Iressa treatment |  | At time of diagnosis and time of patient surgery | 
| To correlate molecular changes with pharmacokinetic parameters |  | At time of diagnosis and time of patient surgery | 
| To evaluate tolerability of short term Iressa treatment |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Iressa, Gefitinib, Breast Cancer, Surgery
Bioequivalence Study of Atazanavir 300 mg Capsule

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical research study is to assess the bioequivalence of atazanavir administered as a single 300 mg capsule relative to two atazanavir 150 mg capsules in healthy subjects.

Official Title
-----------------
Bioequivalence Study of Atazanavir Single 300 mg Capsule Relative to Two Atazanavir 150 mg Capsules in Healthy Subjects

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Atazanavir + Ritonavir
* Drug: Atazanavir + Ritonavir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male and female subjects between the ages of 18 to 50 years old with a body mass index (BMI) of 18 to 30 kg/m² Prior to enrollment, subjects must have physical and laboratory test findings within normal limits, and women of childbearing potential (WOCBP) must have a negative pregnancy test.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br> | Drug: Atazanavir + Ritonavir<br>* Capsules, Oral, ATV 300mg as 2-150mg + RTV 100mg, single dose, 7 days washout crossed over to Treatment B.<br>* Other names: Abilify;|
| Active Comparator: B<br> | Drug: Atazanavir + Ritonavir<br>* Capsules, Oral, ATV 300mg as single cap + RTV 100mg, single dose, 7 days washout.<br>* Other names: Abilify;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood atazanavir pharmacokinetic sampling to be collected on days 1, 2 and 3 of each of the 2 periods of the study |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood ritonavir pharmacokinetic sampling to be collected on days 1, 2 and 3 of each of the 2 periods of the study |  |  | 
| Safety parameters including physical exam (PE), vital signs (VS), electrocardiogram (ECG) and clinical laboratory tests will be collected at study discharge |  |  |
Pharmacogenetics for Pain Management in Joint Replacement Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the ability to use pharmacogenetic testing in a joint replacement practice to prescribe the most effective pain medicine for a specific patient.

Official Title
-----------------
Using Pharmacogenetics to Structure Individual Pain Management Protocols for Joint Replacement Patients

Conditions
-----------------
Arthroplasty Complications

Intervention / Treatment
-----------------
* Diagnostic Test: Pharmacogenomics Testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary total hip or total knee arthroplasty cases Exclusion Criteria: History of narcotic dependence

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control Group<br>Subjects in this arm will receive the standard postoperative pain prescription protocol. | |
| Active Comparator: Pharmacogenomics Guided Group<br>Subjects in this group will receive postoperative pain prescriptions based on the results of pharmacogenomic testing. | Diagnostic Test: Pharmacogenomics Testing<br>* The doctor will use genetic test results to prescribe medications that are a most effective for subject.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genetic variants | Percent of subject with genetic variants affecting pain medication | 10 days postoperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain levels | 0-10 subjective pain scale | 10 days postoperatively |
Evaluation of a Microendoscopic Imaging System in Examination of Resected Tissues

Study Overview
=================
Brief Summary
-----------------
The overall objective of this exploratory, laboratory study is to evaluate whether noninvasive fluorescence microendoscopic imaging of tissue can assist clinicians in detecting dysplastic (precancerous) areas during standard surveillance. This is a study designed to evaluate the feasibility of using prototype imaging technology to enhance the detection of precancerous changes in various tissues. The results of this laboratory study will be used to further develop the technology for clinical application. The primary aim of this project will be to investigate what digital image analysis criteria can be used to best detect dysplasia in various types of resected tissue.

Official Title
-----------------
Evaluation of a Microendoscopic Imaging System in Examination of Resected Tissues

Conditions
-----------------
Known or Suspected Dysplasia or Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females over the age of 18 scheduled for standard of care resection of abnormal tissue Exclusion Criteria: Previous chemotherapy or radiation treatment to the tissue to be resected Inability to provide consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Statistical measurements of the spatial and intensity distributions of pixels within an image | The statistical measurements will be used to correlate each microendoscope image to a histopathology diagnosis. | Up to 24 hours |